With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in the realm of rare disease. | Novo Nordisk has unveiled data from the phase 3 REAL8 trial,

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as effective as a daily shot of Norditropin (somatropin) in children born small for gestational age (SGA), Noonan syndrome (NS), or with idiopathic short stature (ISS).

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later this year.

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo Nordisk's share is decreasing.

LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to approve pharmaceutical plants in the country will significantly change timelines for the pharma industry.